Hui Chen1, Minglin Liang1, Jie Min1. 1. Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Abstract
BACKGROUND: Bevacizumab-combined chemotherapy is a new regimen for advanced/recurrent endometrial cancer. AIMS: To evaluate the efficacy and safety of bevacizumab-combined chemotherapy in advanced/recurrent endometrial cancer. STUDY DESIGN: Systematic review and meta-analysis. METHODS: Eligible studies were retrieved from Embase, PubMed, and Cochrane Library. The data of primary outcomes including progression-free survival and overall survival and secondary outcomes including overall survival, response rate, and adverse events (grade ≥2) were extracted, pooled, and used for the meta-analysis to compare the efficacy and safety of bevacizumab-combined chemotherapy with other treatments in patients with advanced/recurrent endometrial cancer. RESULTS: Notably, 2 randomized-controlled and 5 single-arm trials of bevacizumab-combined chemotherapy or bevacizumab single-agent therapy for endometrial cancer were included. Meta-analysis indicated that bevacizumab-combined chemotherapy significantly increased the progression-free survival rate (hazard ratio=0.82, 95% confidence interval=0.70, 0.97) and overall survival rate (hazard ratio=0.83, 95% confidence interval=0.70, 0.98) compared with chemotherapy alone. The rates of overall, complete, and partial response to bevacizumab-combined chemotherapy were 76%, 22%, and 21%, respectively. The 6 and 12-month disease-free progression rates after bevacizumab-combined chemotherapy were 79% and 62%, respectively. Anemia (23%), leukopenia (46%), neutropenia (51%), hypertension (16%), and fatigue (24%) were the general adverse events after bevacizumab-combined chemotherapy. CONCLUSION: Bevacizumab-combined chemotherapy may have a higher efficacy in improving the overall and progression-free survival in patients with advanced/recurrent endometrial cancers compared with chemotherapy alone.
BACKGROUND: Bevacizumab-combined chemotherapy is a new regimen for advanced/recurrent endometrial cancer. AIMS: To evaluate the efficacy and safety of bevacizumab-combined chemotherapy in advanced/recurrent endometrial cancer. STUDY DESIGN: Systematic review and meta-analysis. METHODS: Eligible studies were retrieved from Embase, PubMed, and Cochrane Library. The data of primary outcomes including progression-free survival and overall survival and secondary outcomes including overall survival, response rate, and adverse events (grade ≥2) were extracted, pooled, and used for the meta-analysis to compare the efficacy and safety of bevacizumab-combined chemotherapy with other treatments in patients with advanced/recurrent endometrial cancer. RESULTS: Notably, 2 randomized-controlled and 5 single-arm trials of bevacizumab-combined chemotherapy or bevacizumab single-agent therapy for endometrial cancer were included. Meta-analysis indicated that bevacizumab-combined chemotherapy significantly increased the progression-free survival rate (hazard ratio=0.82, 95% confidence interval=0.70, 0.97) and overall survival rate (hazard ratio=0.83, 95% confidence interval=0.70, 0.98) compared with chemotherapy alone. The rates of overall, complete, and partial response to bevacizumab-combined chemotherapy were 76%, 22%, and 21%, respectively. The 6 and 12-month disease-free progression rates after bevacizumab-combined chemotherapy were 79% and 62%, respectively. Anemia (23%), leukopenia (46%), neutropenia (51%), hypertension (16%), and fatigue (24%) were the general adverse events after bevacizumab-combined chemotherapy. CONCLUSION: Bevacizumab-combined chemotherapy may have a higher efficacy in improving the overall and progression-free survival in patients with advanced/recurrent endometrial cancers compared with chemotherapy alone.
Authors: Carol Aghajanian; Virginia Filiaci; Don S Dizon; Jay W Carlson; Matthew A Powell; Angeles Alvarez Secord; Krishnansu S Tewari; David P Bender; David M O'Malley; Ashley Stuckey; JianJiong Gao; Fanny Dao; Robert A Soslow; Heather A Lankes; Kathleen Moore; Douglas A Levine Journal: Gynecol Oncol Date: 2018-05-24 Impact factor: 5.482
Authors: Lee M Jampol; Adam R Glassman; Danni Liu; Lloyd Paul Aiello; Neil M Bressler; Elia J Duh; Susan Quaggin; John A Wells; Charles C Wykoff Journal: Ophthalmology Date: 2018-03-07 Impact factor: 12.079
Authors: Carol Aghajanian; Michael W Sill; Kathleen M Darcy; Benjamin Greer; D Scott McMeekin; Peter G Rose; Jacob Rotmensch; Mack N Barnes; Parviz Hanjani; Kimberly K Leslie Journal: J Clin Oncol Date: 2011-05-02 Impact factor: 44.544
Authors: Stacy S Shord; Linda R Bressler; Lauryn A Tierney; Sandra Cuellar; Amina George Journal: Am J Health Syst Pharm Date: 2009-06-01 Impact factor: 2.637
Authors: Jason D Wright; Matthew A Powell; Janet S Rader; David G Mutch; Randall K Gibb Journal: Anticancer Res Date: 2007 Sep-Oct Impact factor: 2.480